FLT3 and acute myeloid leukemia: Since we observed association between concomitant “tumor suppressor”, and “myeloid transcription factors” mutations and decreased sorafenib response, we next explored whether concomitant mutations associated with sorafenib sensitivity using bulk RNA-seq data of bone marrow cells from FLT3-ITD AML patients.